To appraise the clinical and cost-effectiveness of Mirvetuximab soravtansine within its marketing authorisation ovarian cancer, peritoneal cancer, or fallopian tube cancer
Topic is suspended
Status Suspended
Decision Selected
Process TA
ID number 1527


Key events during the development of the guidance:

Date Update
05 March 2021 For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
05 March 2021 Suspended. Topic is suspended
20 May 2019 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
02 May 2019 In progress. Referred on 27 June 2018

For further information on our processes and methods, please see our CHTE processes and methods manual